Skip to main
LUCD

Lucid Diagnostics (LUCD) Stock Forecast & Price Target

Lucid Diagnostics (LUCD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lucid Diagnostics is a high potential company in the commercial-stage medical diagnostics technology sector, with its EsoGuard and EsoCheck having received positive support from medical associations. With progress being made in securing commercial payors, the company currently holds a BUY rating and a price target of $2.50, potentially offering significant growth opportunities. However, financial and regulatory challenges remain as potential risks for the company's future success.

Bears say

Lucid Diagnostics is in the early stages of commercialization which leads to relatively low revenue. The company is facing growth challenges and its financials showed a pro forma net loss of $10.5 million in Q1 with a projected increase in revenue in 2026/27. Although the company has potential for success in the billion-dollar market, the risks may outweigh the potential rewards at this point in time. Lucid has made progress with Medicare coverage but still has not negotiated a price for its services, and the company's inclusion in NCCN guidelines improves its chances of obtaining Medicare coverage, but there are no guarantees. The company's growth drivers include expanding into the LBM market, signing more commercial payers, and increasing collections and revenue from prior period claims, but these are not guaranteed and do not guarantee a positive outlook for the company.

Lucid Diagnostics (LUCD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lucid Diagnostics (LUCD) Forecast

Analysts have given Lucid Diagnostics (LUCD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Lucid Diagnostics (LUCD) has a Strong Buy consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lucid Diagnostics (LUCD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.